Australian based
contract research organisation specialising in
neuroscience and beyond
Epilepsy
Migraine
Huntington’s
Multiple sclerosis
Neuromuscular
Neurosurgery
Parkinson’s
Stroke
psychedelics
Oncology Tracers
Immunology
Ophthalmology
Endocrinology
COVID-19
Devices
Diagnostics
Pain
Mental Health
alzheimer's
Dementia
spinal cord injury
Paediatric Diseases
Psychotic Disorders
Our expertise
NTA is one of the few CRO’s globally that specialises in CNS projects. We also work in other therapeutic areas, which currently include oncology, psychology, infectious diseases, rare paediatric disease, immunology, devices, endocrinology, and COVID-19. NTA supports pharmaceutical, biotechnology, cell therapy and device companies to undertake their phase I-IV clinical trials according to global regulatory standards, including the TGA, FDA and EMA.
Choosing Australia for your clinical research offers very distinct advantages. Australia offers the world’s most attractive R&D cash benefit and an expeditious regulatory environment. You can recover up to 43.5 cents for every dollar you spend on R&D; start your trials without having an IND; and achieve study site start-up within 5-6 weeks because of the TGA’s system of deferment to the Institutional Ethics Committees for study approval.
NTA is a subsidiary of The Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere, which facilitates a unique professional network. NTA has direct access to therapeutic disease specialists, key opinion leaders and clinical trial sites that collectively enable us to deliver quality clinical trial services with strong recruitment outcomes.